We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:


We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.


Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h


ISTH 2019

ISTH 2019
ISTH 2019

Bioxodes presented up-to-date preclinical data during the annual ISTH congress on Sunday 7 July 2019 in Melbourne.

Valérie PireauxA, Joël TassignonA, Stéphanie DemoulinA, Nicolas BorensteinB, Angélique EnteB, Laurence FietteB, Edmond GodfroidA

  • A
    Bioxodes S.A., Marche-en-Famenne, Belgium
  • B
    IMMR, Paris, France


Poster ISTH 2019


Extracorporeal circulation (ECC) during cardiac surgery is a highly thrombogenic procedure involving both intrinsic and extrinsic coagulation pathways and requires strong anticoagulation to prevent thrombosis and to maintain blood fluidity. Unfractionated heparin (UFH) is currently used in such surgical procedures but can lead to serious bleeding complications, highlighting the need for new safer antithrombotic agents. Ir-CPI, a protein from the saliva of tick Ixodes ricinus, is an inhibitor of both FXIIa and FXIa which has been demonstrated to inhibit thrombotic processes in various experimental animal models.


Our objective was to evaluate the efficacy and safety of Ir-CPI in ECC during cardiac surgery using uncoated adult ECC system.


An ECC system with uncoated material was used to perform a chordae replacement and a commissuroplasty of the mitral valve on beating heart of sheep. The ECC was maintained for 90 min at full-flow systemic perfusion level. The investigative group received a bolus followed by a continuous intravenous infusion of Ir-CPI. UFH was used as comparator. Following the procedure, half the animals were kept in recovery for 7 days.


Ir-CPI was proven to be as efficient as UFH in preventing clot formation within the ECC circuit. Moreover, Ir-CPI was shown to be as thromboprotective in the animal as UFH with stable physiological parameters (i.e. blood gases, hematology and biochemistry) up to 7 days post-surgery. Oxygenator membrane examination by scanning electron microscopy showed no differences between Ir-CPI and UFH treatment in terms of protein or blood cell deposits. Animals fully recovered after ECC and cardiac surgery and no hemorrhagic and thrombotic related-Ir-CPI findings were observed after histopathological analyses of organs (heart, kidney, lung, liver, brain, spleen and draining lymph nodes).


These results demonstrate for the first time that a FXIa/FXIIa inhibitor alone provides safe thromboprotection in ECC during cardiac surgery.


Ir-CPI, a FXIa/FXIIa inhibitor, provides an effective and safe thromboprotection during extracorporeal circulation associated with open-heart surgery